BK vs MRSN · P/E 17, $94.14B cap vs rev $40.5M
The Bank of New York Mellon Corporation (BK) versus Mersana Therapeutics Inc (MRSN) — a side-by-side from cached financials, not a winner call.
The Bank of New York Mellon Corporation (BK) is a banks - diversified company listed on US.
Mersana Therapeutics Inc (MRSN) is a biotechnology company listed on NASDAQ.
BK does not have a complete income-statement cache yet.
Latest reported MRSN revenue for 2024-12-31 was $40.5M. Net income was -$69.2M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. MRSN currently screens at market cap $145.4M.
BK currently screens at market cap $94.14B and trailing P/E 17.0. MRSN currently screens at market cap $145.4M.
Not investment advice. Open the BK and MRSN stock pages for the full models.
Not investment advice.